Sponsors (4)
The bill creates a funded, coordinated research effort (with independent biomarker validation) to improve care for veterans exposed to repetitive low-level blasts, but increases data-sharing and federal spending while imposing research mandates that raise privacy and flexibility concerns.
Veterans with likely repetitive low-level blast injuries will receive targeted, sustained research and translational trials (improving diagnosis and treatment) supported by a dedicated $5M/year program and coordinated data resources.
Researchers and clinicians gain a more complete research dataset because VA and DOD data-sharing and consortium inputs create cross-service exposure records that improve study quality and applicability.
Independent biomarker validation and biennial NASEM oversight provide recurring scientific assessment and external credibility to research findings and clinical recommendations.
Service members' and veterans' health and exposure records could face increased privacy and security risks from broader VA–DOD data sharing or placement on an open platform.
The authorized $5M/year (FY2025–2034) raises federal spending and could require higher appropriations or divert funds from other VA priorities and programs.
Mandating specific studies and timelines may constrain VA research flexibility and prioritize certain interventions over other promising approaches or local research priorities.
Based on analysis of 2 sections of legislative text.
Expands VA precision-medicine work to include repetitive low-level blast exposure and dementia, mandates DOD data sharing and multiple large-scale studies, requires NASEM validation and reports, and authorizes $5M/yr (FY2025–2034).
Amends VA law to expand the Precision Medicine for Veterans Initiative to explicitly cover repetitive low-level blast exposure and dementia, require Department of Defense data sharing onto the initiative’s open platform, and direct a slate of large-scale research, implementation, and quality-improvement studies. The VA must contract with the National Academies for biomarker validation and provide regular reports and assessments to congressional Veterans’ Affairs committees; the law authorizes $5,000,000 per year for FY2025–2034 to support the initiative.
Introduced February 27, 2025 by Jerry Moran · Last progress February 27, 2025